17. Recent Results Cancer Res. 2018;211:199-215. doi: 10.1007/978-3-319-91442-8_14.Afatinib.Wecker H(1), Waller CF(2).Author information: (1)Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, and Faculty of Medicine, University of Freiburg,Hugstetter Str. 55, 79106, Freiburg, Germany.(2)Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, and Faculty of Medicine, University of Freiburg,Hugstetter Str. 55, 79106, Freiburg, Germany.cornelius.waller@uniklinik-freiburg.de.Afatinib (BIBW 2992, US: GilotrifTM, other countries: GiotrifÂ©) is anirreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by the FDA and the EMA for the treatment ofadults with advanced, EGFR mutation-positive non-small-cell lung cancer. Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast cancer, are ongoing.DOI: 10.1007/978-3-319-91442-8_14 PMID: 30069769 